文献速递呼吸危重症与机械通气

高流量鼻导管治疗对实验性呼吸困难缓解的内在益处:健康人实验室随机试验

Dyspnoea relief as an inherent benefit of high flow nasal cannula therapy: A laboratory randomized trial in healthy humans.
PubMed 文献 · Respirology · 2023-09-01

结果显示两种FiO2的HFNT均显著降低呼吸困难的感觉与情感评分,且两者间无显著差异,提示HFNT缓解呼吸困难不依赖于氧浓度增加。

要点

  • HFNT可显著降低实验性呼吸困难的感觉与情感评分,且不依赖FiO2水平。
  • HFNT21与HFNT100在缓解呼吸困难方面无显著差异。
  • HFNT未显著改变呼吸频率或心率,仅在室内空气条件下降低PtcCO2。

核心结论

  • HFNT与呼吸困难感觉和情感成分强度的统计学显著降低相关,且不依赖于氧气的添加。

研究设计与样本

  • HFNT分别以FiO2 100%(HFNT100)或21%(HFNT21)交替给予,随机顺序测试。
  • 共进行三次8分钟实验会话:第一次熟悉实验性呼吸困难,后两次随机测试HFNT100和HFNT21的效果。

主要发现

  • HFNT21显著降低情感评分(∆A-VAS = 0.80 cm [-0.02-1.5];p = 0.007)和感觉评分(∆S-VAS = 0.70 cm [-0.15-1.98];p < 0.0001)。
  • HFNT100显著降低情感评分(∆A-VAS = 1.00 cm [0.08-1.75];p < 0.0001)和感觉评分(∆S-VAS = 0.70 cm [0.08-1.95];p = 0.0002)。
  • HFNT21与HFNT100之间无显著差异。
  • HFNT未显著改变呼吸频率或心率,仅在室内空气条件下降低PtcCO2,两种实验条件下均降低皮肤电反应(GSR)。

临床怎么用

  • HFNT可能作为缓解呼吸困难的治疗手段,其效果不依赖于提高FiO2。
  • 机制可能与减少传入-再传入不匹配有关。

局限性

  • 研究为健康人实验性呼吸困难模型,结果不能直接外推至临床患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Persistent dyspnoea is a public health issue for which the therapeutic arsenal is limited. This study tested high-flow nasal cannula therapy (HFNT) as a means to alleviate experimental dyspnoea. METHODS: Thirty-two healthy subjects underwent an experimental dyspnoea induced by thoracoabdominal elastic loading. HFNT was administered with alternately FiO2 of 100% (HFNT100) or 21% (HFNT21). The sensory (S-VAS) and affective (A-VAS) components of dyspnoea, transcutaneous CO2 pressure (PtcCO2 ), pulse-oximetry oxygen saturation (SpO2 ), heart rate, respiratory rate and skin galvanometry were monitored continuously. Three experimental sessions of 8 min were conducted: the first session consisted in familiarization with the experimental dyspnoea and the next two sessions tested the effects of HFNT100 and HFNT21 alternatively in a randomized order. RESULTS: HFNT21 and HFNT100 significantly reduced dyspnoea, respectively of ∆A-VAS = 0.80 cm [-0.02-1.5]; p = 0.007 and ∆A-VAS = 1.00 cm [0.08-1.75]; p < 0.0001; ∆S-VAS = 0.70 cm [-0.15-1.98]), p < 0.0001 and ∆S-VAS = 0.70 cm [0.08-1.95]), p = 0.0002) with no significant difference between HFNT21 and HFNT100. HFNT did not significantly alter the respiratory rate or the heart rate, reduced PtcCO2 only on room air and GSR under both experimental conditions. CONCLUSION: HFNT was associated with a statistically significant reduction in the intensity of the sensory and affective components of dyspnoea, independent of oxygen addition. This relief of laboratory dyspnoea could result from a reduction of afferent-reafferent mismatch.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Bianquis C, Rolland-Debord C, Rivals I, et al. Dyspnoea relief as an inherent benefit of high flow nasal cannula therapy: A laboratory randomized trial in healthy humans. Respirology. 2023. PMID: 37656056. doi:10.1111/resp.14580

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。